報價延遲最少15分鐘:2024/12/24 12:42 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.53 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.44/-3.70
|
|
企業價值
713.67M
|
| 資產負債 |
|
每股賬面淨值
11.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
129.01M
|
|
每股收益
2.33
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:42 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion. |